首页> 美国卫生研究院文献>Journal of the Endocrine Society >SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study
【2h】

SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study

机译:SAT-391常规治疗与钙和活化维生素D患者慢性术后患者患者的安全性和有效性:横截面案例对照研究的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: Conventional therapy of chronic post-operative hypoparathyroidism (PO-HypoPT) with calcium and activated vitamin D is suboptimal and associated with several complications, including impairment of the quality of life. Aim of this study was to compare clinical, biochemical and instrumental parameters in 120 patients who underwent total thyroidectomy for differentiated thyroid cancer, 60 with PO-HypoPT (Group A) treated with conventional therapy and 60 without (Group B), matched for age and sex, followed a tertiary referral center. Matherials and methods: An “ad hoc” CRF was used to collect epidemiological, clinical (symptoms, treatment) and biochemical data (total and ionized calcium, albumin, phosphate, magnesium, calcium/phosphate product, creatinine, 25-OH vitamin D, PTH, TSH, eGFR, 24-h urinary calcium and creatinine), and renal ultrasound. Results: The median duration of PO-HypoPT was 7 years (IQR 4-13). All patients of group A were treated with calcitriol (median 0.5 μg/daily; IQR 0.5-1.0), and 33/60 (55%) were also given calcium carbonate supplementation (median 1000 mg/daily; IQR 500-1000). Hypocalcemia related symptoms were more frequent in group A (27/60 - 45%) than in group B (1/60 - 1.7%) (p<0.01). Total and ionized serum calcium [median 8.9 (IQR 8.5-9.1) vs 9.3 (IQR 9.0-9.5) mg/dl; median 1.16 (IQR 1.1-1.2) vs 1.23 (IQR 1.21-1.27) mmol/L] (p<0.01), magnesium [median 1.9 (IQR 1.8-2.0) vs 2 (IQR 1.9-2.1) mg/dl - p<0.01] and PTH [median 10 (IQR 8-13) vs 29 (IQR 22-35) pg/ml - p<0.01] were significantly lower in Group A vs Group B. Conversely, serum phosphate [median 3.7 (IQR 3.4-4.1) vs 3.3 (IQR 3.0-3.6) mg/dl - p<0.01], calcium-phosphate product [median 33 (IQR 30-36) vs 30 (IQR 27-34) - p=0.012] and 25-OH vitamin D [median 34.1 (IQR 29.2-41.3) vs 26.7 (IQR 18.1-33.4) - p<0.01) were significantly higher in Group A vs Group B. Twenty-four hour urinary calcium was higher in group A [median 248 mg (IQR 166-363)] than in group B [median 165 mg (IQR 94-229)] (p<0.01). The rate of nephrolithiasis was significantly higher in group A (21/60 pts - 35%) than in group B (7/60 pts - 11.7%) (p<0.01). Moreover, there was a significant correlation of neprholithiasis with 24h urinary calcium but not with total and ionized serum calcium. Conclusions: This cross-sectional case-control study confirms that treatment of chronic PO-HypoPT with conventional therapy is suboptimal, even in a tertiary referral center, and associated with an increased risk of nephrolithiasis. Following the recent publication of treatment guidelines, the question of whether a better quality of care, including the use of rhPTH, will improve the biochemical control and decrease the rate of hypercalciuria and the risk of nephrolithiasis remains to be established.
机译:介绍:慢性术后甲状旁腺功能减退(PO-HypoPT)的常规治疗与钙和活化维生素d是次优的,并用几个并发症,包括生活质量的损害相关联。这项研究的目的是比较120例谁接受了分化型甲状腺癌甲状腺全切除术,60与常规治疗和60无(B组)PO-HypoPT(A组)临床,生化和仪器参数,年龄匹配,性别,其次三级转诊中心。 Matherials和方法:一个“特别” CRF用于收集流行病学,临床(症状,治疗)和生化数据(总的和离子化钙,白蛋白,磷酸盐,镁,钙/磷酸盐产品,肌酸酐,25-羟维生素d, PTH,TSH,EGFR,24小时尿的钙和肌酸酐),和肾超声。结果:PO-HypoPT的时间中位数为7年(IQR 4-13)。 A组的所有患者均接受钙三醇处理(中位数0.5微克/每天; IQR 0.5-1.0)和33/60(55%)也分别给予碳酸钙补充(中位数1000毫克/每天; IQR 500-1000)。比在B组 - 低钙血症相关的症状是在基团A(45%27/60)更频繁的(1/60 - 1.7%)(P <0.01)。总和离子化的血清钙[中值8.9(IQR 8.5-9.1)比9.3(IQR 9.0-9.5)毫克/分升;中位数1.16(IQR 1.1-1.2)与1.23(IQR 1.21-1.27)毫摩尔/ L](P <0.01),镁[​​中位数1.9(IQR 1.8-2.0)与2(IQR 1.9-2.1)毫克/分升 - P < 0.01]和PTH [中值10(IQR 8-13)与29(IQR 22-35)微克/毫升 - p <0.01]在A组显著降低相对于组B.相反,血清磷酸盐[中位数3.7(IQR 3.4- 4.1)与3.3(IQR 3.0-3.6)毫克/分升 - p <0.01],磷酸钙产物[33中位数(IQR 30-36)与30(IQR 27-34) - p = 0.012]和25-OH维生素d [中值34.1(IQR 29.2-41.3)26.7 VS(IQR 18.1-33.4) - p <0.01),A组是显著更高相对于组B.二十四小时的尿钙是A组更高[中位数248毫克(IQR 166-363)]比在B组[中位数165毫克(IQR 94-229)](p <0.01)。肾结石率为A组(21/60分 - 35%)显著高于B组(60分之7PTS - 11.7%)(P <0.01)。此外,有一个与24小时尿钙neprholithiasis的显著相关,但不与总和离子化血清钙。结论:该横截面的病例对照研究证实了治疗慢性PO-HypoPT的常规治疗是次优的,即使是在三级转诊中心,并与肾结石的风险增加相关联。在最近的治疗指南发布,以建立更好的医疗质量,包括使用的rhPTH是否会提高生化控制和减少尿钙的速度和残留肾结石的风险问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号